Alpha memo: resveratrol exercise training translation boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Tighten the alpha sentence to remove the ambiguous word 'tissue' — Receipt 1 is specifically intestinal tissue/ferroptosis, so the bounded signal should say 'intestinal tissue' or 'gut' rather than the generic 'stressed tissue'.
2. Consider noting in the caveats that the two receipts also differ in endpoint type (intestinal histology/inflammation vs. VO2max/cardiovascular), which is itself a plausible moderator beyond species/dose.
3. Add a brief note that the rodent study (2023) post-dates the human trial (2013), so the translation-boundary framing is not about contradictory contemporaneous findings but about a mechanistic adjunct reading vs. a clinical blunting reading.

Minor issues

• Gaps are present but could be more specific/actionable — e.g., what exact dose, species, or endpoint design would adjudicate between rodent protection and human VO2max blunting.

Reviewer note

This is a competent alpha memo that identifies a real tension between two source-grounded receipts: rodent evidence that resveratrol protects intestinal tissue during high-intensity exercise, and a small human trial suggesting blunted VO2max gains with resveratrol + training in older men. The title/source alignment is correct — both receipts are resveratrol + exercise training studies, and the anchor compounds match. The novelty claim is appropriately bounded: the memo does not claim resveratrol is good or bad, only that the net direction depends on population/endpoint, which is a defensible synthesis from the two cited studies. Claim-evidence alignment is good; the memo uses hedging language ('may protect', 'may blunt') proportionate to the evidence. Limitations are specific and material (species, dose, duration, baseline activity, small n=27). Gaps could be more specific — what trial design would falsify the blunting finding is partially stated but could be sharpened. No major issues. Minor revisions: (1) the abstract's 'stressed tissue' is vague given Receipt 1 is specifically intestinal; (2) endpoint type (gut histology vs. VO2max) is a confound worth flagging alongside species/dose; (3) noting the 2023-vs-2013 chronology would strengthen the framing. Revise rather than accept because the abstract-level wording could mislead about the specificity of the rodent endpoint.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis